168 related articles for article (PubMed ID: 19359706)
21. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
De Jesus Moreno Moreno M
Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
[TBL] [Abstract][Full Text] [Related]
22. Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.
Irizarry MC; Webb DJ; Bains C; Barrett SJ; Lai RY; Laroche JP; Hosford D; Maher-Edwards G; Weil JG
J Alzheimers Dis; 2008 Jul; 14(3):301-11. PubMed ID: 18599956
[TBL] [Abstract][Full Text] [Related]
23. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
[TBL] [Abstract][Full Text] [Related]
24. Neuropsychological and psychiatric differences between Alzheimer's disease and Parkinson's disease with dementia.
Starkstein SE; Sabe L; Petracca G; Chemerinski E; Kuzis G; Merello M; Leiguarda R
J Neurol Neurosurg Psychiatry; 1996 Oct; 61(4):381-7. PubMed ID: 8890777
[TBL] [Abstract][Full Text] [Related]
25. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
26. The Danish version of the Baylor Profound Mental State Examination.
Kørner A; Brogaard A; Wissum I; Petersen U
Nord J Psychiatry; 2012 Jun; 66(3):198-202. PubMed ID: 21992015
[TBL] [Abstract][Full Text] [Related]
27. Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease.
Aarsland D; Litvan I; Salmon D; Galasko D; Wentzel-Larsen T; Larsen JP
J Neurol Neurosurg Psychiatry; 2003 Sep; 74(9):1215-20. PubMed ID: 12933921
[TBL] [Abstract][Full Text] [Related]
28. Psychometric Properties of Alzheimer's Disease Assessment Scale-Cognitive Subscale for Mild Cognitive Impairment and Mild Alzheimer's Disease Patients in an Asian Context.
Zainal NH; Silva E; Lim LL; Kandiah N
Ann Acad Med Singap; 2016 Jul; 45(7):273-83. PubMed ID: 27523508
[TBL] [Abstract][Full Text] [Related]
29. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
30. [Is it pseudo-dementia? The validation of the Adas-Cog questionnaire in Hungary].
Drótos G; Pákáski M; Papp E; Kálmán J
Psychiatr Hung; 2012; 27(2):82-91. PubMed ID: 22700619
[TBL] [Abstract][Full Text] [Related]
31. Reliability, validity, and diagnostic accuracy of Parkinson's Disease-Cognitive Rating Scale in Iranian patients with idiopathic Parkinson's disease.
Mahmoudi Asl A; Mehdizadeh M; Kulisevsky J; Sabet A; Taghavi Azar Sharabiani P; Mehdizadeh H; Ashayeri H; Taghizadeh G
Disabil Rehabil; 2022 May; 44(10):2091-2098. PubMed ID: 32924645
[TBL] [Abstract][Full Text] [Related]
32. [Comparison of cognitive functions and neuropsychiatric symptoms between patients with Parkinson's disease dementia and Alzheimer's disease].
Tang Y; Ji XJ; Xing Y; Zuo XM; Zhou AH; Jia JP
Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2459-62. PubMed ID: 24300264
[TBL] [Abstract][Full Text] [Related]
33. Validity of the Dementia Rating Scale in assessing cognitive function in Parkinson's disease.
Brown GG; Rahill AA; Gorell JM; McDonald C; Brown SJ; Sillanpaa M; Shults C
J Geriatr Psychiatry Neurol; 1999; 12(4):180-8. PubMed ID: 10616865
[TBL] [Abstract][Full Text] [Related]
34. The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients. Metrifonate Study Group.
Raskind MA; Cyrus PA; Ruzicka BB; Gulanski BI
J Clin Psychiatry; 1999 May; 60(5):318-25. PubMed ID: 10362441
[TBL] [Abstract][Full Text] [Related]
35. Addenbrooke's Cognitive Examination validation in Parkinson's disease.
Reyes MA; Perez-Lloret S; Roldan Gerschcovich E; Martin ME; Leiguarda R; Merello M
Eur J Neurol; 2009 Jan; 16(1):142-7. PubMed ID: 19049504
[TBL] [Abstract][Full Text] [Related]
36. Reliability of the Alzheimer's disease assessment scale (ADAS-Cog) in longitudinal studies.
Khan A; Yavorsky C; DiClemente G; Opler M; Liechti S; Rothman B; Jovic S
Curr Alzheimer Res; 2013 Nov; 10(9):952-63. PubMed ID: 24117118
[TBL] [Abstract][Full Text] [Related]
37. Apathy and related executive syndromes in dementia associated with Parkinson's disease and in Alzheimer's disease.
Grossi D; Santangelo G; Barbarulo AM; Vitale C; Castaldo G; Proto MG; Siano P; Barone P; Trojano L
Behav Neurol; 2013 Jan; 27(4):515-22. PubMed ID: 23242363
[TBL] [Abstract][Full Text] [Related]
38. [Rapid Disability Rating Scale-2 in Alzheimer's disease: NORMACODEM project data].
Monllau A; Aguilar M; Peña-Casanova J; Böhm P; Blesa R; Sol JM; Hernández G;
Neurologia; 2006; 21(6):282-8. PubMed ID: 16799902
[TBL] [Abstract][Full Text] [Related]
39. Cognitive conditions of pathologically confirmed dementia with Lewy bodies and Parkinson's disease with dementia.
Horimoto Y; Matsumoto M; Nakazawa H; Yuasa H; Morishita M; Akatsu H; Ikari H; Yamamoto T; Kosaka K
J Neurol Sci; 2003 Dec; 216(1):105-8. PubMed ID: 14607310
[TBL] [Abstract][Full Text] [Related]
40. People with Parkinson's disease and normal MMSE score have a broad range of cognitive performance.
Burdick DJ; Cholerton B; Watson GS; Siderowf A; Trojanowski JQ; Weintraub D; Ritz B; Rhodes SL; Rausch R; Factor SA; Wood-Siverio C; Quinn JF; Chung KA; Srivatsal S; Edwards KL; Montine TJ; Zabetian CP; Leverenz JB
Mov Disord; 2014 Sep; 29(10):1258-64. PubMed ID: 25073717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
